The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Toxicity in combined modality treatment of HNSCC: Cisplatin versus cetuximab.
A. Chew
No relevant relationships to disclose
J. Hay
No relevant relationships to disclose
J. J. Laskin
No relevant relationships to disclose
J. Wu
No relevant relationships to disclose
C. Ho
Honoraria - Bristol-Myers Squibb